Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Posts positive from its Phase 2 clinical trial of inhaled SNG001 in virally infected chronic obstructive pulmonary disease patients. Says findings from assessments of lung sputum samples show viral clearance from the lower respiratory tract. SNG001 is a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta.
Says the SG015 trial was paused due to Covid-19 in early 2020. In September 2020, an interim analysis showed SNG001 boosted lung antiviral responses as assessed using sputum biomarkers, and led to a significant difference in the lung function of exacerbating patients.
Chief Executive Officer Richard Marsden says: "Our new data from COPD patients shows that SNG001 can accelerate viral clearance from the lung and builds on our existing data supporting SNG001's mechanism of action and our focus on severe viral lung infections. This additional assessment supports continued and further investigation of SNG001 as a possible broad-spectrum antiviral."
Current stock price: 23.20 pence, up 5.5%
12-month change: down 85%
By Xindi Wei; xindiwei@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)